Illumina Cambridge Limited is a privately held limited company established in 1998 and currently active. Located at 19 Granta Park, Cambridge, CB21 6DF, Illumina specializes in the design, development, and commercialization of advanced sequencing and array technologies. The company’s core business revolves around providing cutting-edge solutions for life science research, facilitating advancements across diverse sectors. Illumina’s primary focus is on supporting the research and development efforts of biotechnology companies, pharmaceutical firms, and academic institutions. They offer a comprehensive portfolio of sequencing and array products, including DNA sequencing, gene expression analysis, and targeted sequencing technologies. These technologies are instrumental in genomic research, personalized medicine, and the development of novel diagnostics. The company’s services cater to a broad range of applications, including gene discovery, variant interpretation, and biomarker identification. Illumina’s global reach extends beyond its Cambridge headquarters, with a limited international presence primarily focused on strategic partnerships and collaborations. The company operates under the SIC code -72110, representing the research and experimental development sector within the biotechnology industry.

Illumina Cambridge Limited is a privately held limited company established in 1998 and currently active. Located at 19 Granta Park, Cambridge, CB21 6DF, Illumina specializes in the design, development, and commercialization of advanced sequencing and array technologies. The company’s core business revolves around providing cutting-edge solutions for life science research, facilitating advancements across diverse sectors. Illumina’s primary focus is on supporting the research and development efforts of biotechnology companies, pharmaceutical firms, and academic institutions. They offer a comprehensive portfolio of sequencing and array products, including DNA sequencing, gene expression analysis, and targeted sequencing technologies. These technologies are instrumental in genomic research, personalized medicine, and the development of novel diagnostics. The company’s services cater to a broad range of applications, including gene discovery, variant interpretation, and biomarker identification. Illumina’s global reach extends beyond its Cambridge headquarters, with a limited international presence primarily focused on strategic partnerships and collaborations. The company operates under the SIC code -72110, representing the research and experimental development sector within the biotechnology industry.